172 related articles for article (PubMed ID: 35368828)
1. The Relationship between APOL1 Structure and Function: Clinical Implications.
Madhavan SM; Buck M
Kidney360; 2021 Jan; 2(1):134-140. PubMed ID: 35368828
[TBL] [Abstract][Full Text] [Related]
2. APOL1 Nephropathy: From Genetics to Clinical Applications.
Friedman DJ; Pollak MR
Clin J Am Soc Nephrol; 2021 Feb; 16(2):294-303. PubMed ID: 32616495
[TBL] [Abstract][Full Text] [Related]
3. Recruitment of APOL1 kidney disease risk variants to lipid droplets attenuates cell toxicity.
Chun J; Zhang JY; Wilkins MS; Subramanian B; Riella C; Magraner JM; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2019 Feb; 116(9):3712-3721. PubMed ID: 30733285
[TBL] [Abstract][Full Text] [Related]
4. Apolipoprotein L1 and mechanisms of kidney disease susceptibility.
Bruggeman LA; Sedor JR; O'Toole JF
Curr Opin Nephrol Hypertens; 2021 May; 30(3):317-323. PubMed ID: 33767059
[TBL] [Abstract][Full Text] [Related]
5. APOL1 risk variants in kidney transplantation: a modulation of immune cell function.
Malone AF
J Clin Invest; 2021 Nov; 131(22):. PubMed ID: 34779415
[TBL] [Abstract][Full Text] [Related]
6. Association between
Jiang L; Liu G; Oeser A; Ihegword A; Dickson AL; Daniel LL; Hung AM; Cox NJ; Chung CP; Wei WQ; Stein CM; Feng Q
Elife; 2023 Oct; 12():. PubMed ID: 37882666
[TBL] [Abstract][Full Text] [Related]
7. A Brief History of APOL1: A Gene Evolving.
Friedman DJ
Semin Nephrol; 2017 Nov; 37(6):508-513. PubMed ID: 29110757
[TBL] [Abstract][Full Text] [Related]
8. APOL1 kidney disease risk variants cause cytotoxicity by depleting cellular potassium and inducing stress-activated protein kinases.
Olabisi OA; Zhang JY; VerPlank L; Zahler N; DiBartolo S; Heneghan JF; Schlöndorff JS; Suh JH; Yan P; Alper SL; Friedman DJ; Pollak MR
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):830-7. PubMed ID: 26699492
[TBL] [Abstract][Full Text] [Related]
9.
Friedman DJ; Pollak MR
Annu Rev Physiol; 2020 Feb; 82():323-342. PubMed ID: 31710572
[TBL] [Abstract][Full Text] [Related]
10. Kidney-disease-associated variants of Apolipoprotein L1 show gain of function in cation channel activity.
Bruno J; Edwards JC
J Biol Chem; 2021; 296():100238. PubMed ID: 33380423
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.
Lannon H; Shah SS; Dias L; Blackler D; Alper SL; Pollak MR; Friedman DJ
Kidney Int; 2019 Dec; 96(6):1303-1307. PubMed ID: 31611067
[TBL] [Abstract][Full Text] [Related]
12. Genetic risk of APOL1 and kidney disease in children and young adults of African ancestry.
Reidy KJ; Hjorten R; Parekh RS
Curr Opin Pediatr; 2018 Apr; 30(2):252-259. PubMed ID: 29406442
[TBL] [Abstract][Full Text] [Related]
13. Host factors predisposing to kidney disease in people with HIV.
Hung RKY; Winkler CA; Post FA
Curr Opin HIV AIDS; 2023 Mar; 18(2):87-92. PubMed ID: 36722197
[TBL] [Abstract][Full Text] [Related]
14. Association of APOL1 variants with mild kidney disease in the first-degree relatives of African American patients with non-diabetic end-stage renal disease.
Freedman BI; Langefeld CD; Turner J; Núñez M; High KP; Spainhour M; Hicks PJ; Bowden DW; Reeves-Daniel AM; Murea M; Rocco MV; Divers J
Kidney Int; 2012 Oct; 82(7):805-11. PubMed ID: 22695330
[TBL] [Abstract][Full Text] [Related]
15. Dilemmas and challenges in apolipoprotein L1 nephropathy research.
Kruzel-Davila E; Skorecki K
Curr Opin Nephrol Hypertens; 2019 Jan; 28(1):77-86. PubMed ID: 30431460
[TBL] [Abstract][Full Text] [Related]
16. APOL1 at 10 years: progress and next steps.
Freedman BI; Kopp JB; Sampson MG; Susztak K
Kidney Int; 2021 Jun; 99(6):1296-1302. PubMed ID: 33794228
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein L1 and kidney transplantation.
Tedla FM; Yap E
Curr Opin Organ Transplant; 2019 Feb; 24(1):97-102. PubMed ID: 30507707
[TBL] [Abstract][Full Text] [Related]
18. APOL1-Mediated Kidney Disease.
Hopper T; Olabisi OA
JAMA; 2024 May; 331(19):1668-1669. PubMed ID: 38662391
[TBL] [Abstract][Full Text] [Related]
19.
Grams ME; Surapaneni A; Ballew SH; Appel LJ; Boerwinkle E; Boulware LE; Chen TK; Coresh J; Cushman M; Divers J; Gutiérrez OM; Irvin MR; Ix JH; Kopp JB; Kuller LH; Langefeld CD; Lipkowitz MS; Mukamal KJ; Musani SK; Naik RP; Pajewski NM; Peralta CA; Tin A; Wassel CL; Wilson JG; Winkler CA; Young BA; Zakai NA; Freedman BI
J Am Soc Nephrol; 2019 Oct; 30(10):2027-2036. PubMed ID: 31383730
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein L1 Testing in African Americans: Involving the Community in Policy Discussions.
Young BA; Blacksher E; Cavanaugh KL; Freedman BI; Fullerton SM; Kopp JB; Umeukeje EM; West KM; Wilson JG; Burke W;
Am J Nephrol; 2019; 50(4):303-311. PubMed ID: 31480040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
